Evidence map›Paper›PMID 37899778›Full record

ArticleNeuro-oncology advances

Quantitative analysis of

David Gibson, Akshay Ravi, Eduardo Rodriguez, Susan Chang, Nancy Oberheim Bush, Jennie Taylor, Jennifer Clarke, David Solomon, Aaron Scheffler, John Witte and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. A Genomically Tailored Multiagent Precision Medicine Clinical Trial for Adults with Recurrent Glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

David GibsonDepartment of Neurological Surgery, Division of Neuro-Oncology, University of California, San Francisco, California, USA.ORCID https://orcid.org/0000-0002-3695-1831
Akshay RaviDepartment of Neurological Surgery, Division of Neuro-Oncology, University of California, San Francisco, California, USA.
Eduardo RodriguezDepartment of Neurological Surgery, Division of Neuro-Oncology, University of California, San Francisco, California, USA.
Susan ChangDepartment of Neurological Surgery, Division of Neuro-Oncology, University of California, San Francisco, California, USA.
Nancy Oberheim BushDepartment of Neurological Surgery, Division of Neuro-Oncology, University of California, San Francisco, California, USA.
Jennie TaylorDepartment of Neurological Surgery, Division of Neuro-Oncology, University of California, San Francisco, California, USA.ORCID https://orcid.org/0000-0003-3980-5626
Jennifer ClarkeDepartment of Neurological Surgery, Division of Neuro-Oncology, University of California, San Francisco, California, USA.ORCID https://orcid.org/0000-0002-8054-7342
David SolomonDepartment of Neurological Surgery, Division of Neuro-Oncology, University of California, San Francisco, California, USA.
Aaron SchefflerDepartment of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
John WitteDepartment of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
Hannah LambingDepartment of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
Hideho OkadaDepartment of Neurological Surgery, Division of Neuro-Oncology, University of California, San Francisco, California, USA.ORCID https://orcid.org/0000-0003-0076-9920
Mitchel BergerDepartment of Neurological Surgery, Division of Neuro-Oncology, University of California, San Francisco, California, USA.
Farid ChehabInstitute for Human Genetics, University of California, San Francisco, California, USA.
Nicholas A ButowskiDepartment of Neurological Surgery, Division of Neuro-Oncology, University of California, San Francisco, California, USA.
University of California, San Francisco · US

Funding

Preclinical development of breakthrough immunotherapy for brain tumorsR35NS105068 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI OKADA, HIDEHO · 2018 to 2025
$6.0M
NINDS NIH HHS R35 NS105068
6 · The paper itself

Abstract

Background: Epigenetic inhibition of the Methods: A CLIA assay and bisulfite sequencing was utilized to develop a quantitative, 17-point, Results: Median follow-up time and progression-free survival were 16 and 9 months, respectively. A total of 176 subjects experienced death. A one-unit increase in promoter CpG methylation resulted in a 4% reduction in hazard (95% CI 0.93-0.99, Conclusions: Our findings suggest that the relationship between the extent of

Indexed as

bisulfite sequencingCpGglioblastomamethylationMGMT

Identifiers

PMID37899778
PMCPMC10611422
OpenAlexW4386862183

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.